TRIM59 Promotes Retinoblastoma Progression by Activating the p38-MAPK Signaling Pathway. 2020

Chao Wu, and Xue-Qin Shang, and Zhi-Peng You, and Qi-Fang Jin, and Yu-Lan Zhang, and Yue Zhou, and Yue-Zhi Zhang, and Ke Shi
,.

Retinoblastoma is a malignant tumor of the developing retina that mostly occurs in children. Our study aimed to investigate the effect of tripartite motif-containing protein 59 (TRIM59) on retinoblastoma growth and the underlying mechanisms. We performed bioinformatic analysis of three datasets (GSE24673, GSE97508, and GSE110811) from the Gene Expression Omnibus database. Quantitative reverse-transcription PCR and immunoblotting of three retinoblastoma cell lines were conducted to verify TRIM59 as a differentially expressed gene. Specific siRNAs were used to inhibit TRIM59 expression in the HXO-Rb44 cell line. A lentiviral vector was transfected into the Y79 cell line to overexpress TRIM59. The effects of TRIM59 on retinoblastoma cell proliferation, cell cycling, and apoptosis were explored in vitro using the abovementioned cell lines. The effect of TRIM59 expression on retinoblastoma cell proliferation was evaluated in a mouse xenograft tumor model. TRIM59 expression in three retinoblastoma cell lines was remarkably elevated compared with normal control. Knocking down TRIM59 expression remarkably suppressed cell proliferation and growth and promoted cell apoptosis in HXO-Rb44 cells, whereas TRIM59 overexpression promoted tumor progression in Y79 cells. Silencing TRIM59 also markedly inhibited in vivo tumor growth in the xenograft model. Mechanistic studies revealed that TRIM59 upregulated phosphorylated p38, p-JNK1/2, p-ERK1/2, and p-c-JUN expression in retinoblastoma cells. Notably, the p38 inhibitor SB203580 attenuated the effects of TRIM59 on cell proliferation, apoptosis, and the G1/S phase transition. TRIM59 plays an oncogenic role in retinoblastoma and exerts its tumor-promotive function by activating the p38-mitogen-activated protein kinase pathway.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008819 Mice, Nude Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses. Athymic Mice,Mice, Athymic,Nude Mice,Mouse, Athymic,Mouse, Nude,Athymic Mouse,Nude Mouse
D010766 Phosphorylation The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety. Phosphorylations
D002453 Cell Cycle The complex series of phenomena, occurring between the end of one CELL DIVISION and the end of the next, by which cellular material is duplicated and then divided between two daughter cells. The cell cycle includes INTERPHASE, which includes G0 PHASE; G1 PHASE; S PHASE; and G2 PHASE, and CELL DIVISION PHASE. Cell Division Cycle,Cell Cycles,Cell Division Cycles,Cycle, Cell,Cycle, Cell Division,Cycles, Cell,Cycles, Cell Division,Division Cycle, Cell,Division Cycles, Cell
D002465 Cell Movement The movement of cells from one location to another. Distinguish from CYTOKINESIS which is the process of dividing the CYTOPLASM of a cell. Cell Migration,Locomotion, Cell,Migration, Cell,Motility, Cell,Movement, Cell,Cell Locomotion,Cell Motility,Cell Movements,Movements, Cell
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D005822 Genetic Vectors DNA molecules capable of autonomous replication within a host cell and into which other DNA sequences can be inserted and thus amplified. Many are derived from PLASMIDS; BACTERIOPHAGES; or VIRUSES. They are used for transporting foreign genes into recipient cells. Genetic vectors possess a functional replicator site and contain GENETIC MARKERS to facilitate their selective recognition. Cloning Vectors,Shuttle Vectors,Vectors, Genetic,Cloning Vector,Genetic Vector,Shuttle Vector,Vector, Cloning,Vector, Genetic,Vector, Shuttle,Vectors, Cloning,Vectors, Shuttle
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000070584 Tripartite Motif Proteins A protein family defined by the presence of three ZINC FINGER domains, one of which is a RING FINGER DOMAIN, a coiled-coil region, and a highly variable C-terminal region. They function in many cellular processes including APOPTOSIS and CELL CYCLE regulation. RBCC Protein,TRIM Protein,Tripartite Motif Protein,RBCC Protein Family,RBCC Proteins,TRIM Protein Family,TRIM Proteins,Family, RBCC Protein,Family, TRIM Protein,Motif Protein, Tripartite,Motif Proteins, Tripartite,Protein Family, RBCC,Protein Family, TRIM,Protein, RBCC,Protein, TRIM,Protein, Tripartite Motif,Proteins, RBCC,Proteins, TRIM,Proteins, Tripartite Motif
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

Chao Wu, and Xue-Qin Shang, and Zhi-Peng You, and Qi-Fang Jin, and Yu-Lan Zhang, and Yue Zhou, and Yue-Zhi Zhang, and Ke Shi
May 2019, Oncology reports,
Chao Wu, and Xue-Qin Shang, and Zhi-Peng You, and Qi-Fang Jin, and Yu-Lan Zhang, and Yue Zhou, and Yue-Zhi Zhang, and Ke Shi
April 2020, PLoS genetics,
Chao Wu, and Xue-Qin Shang, and Zhi-Peng You, and Qi-Fang Jin, and Yu-Lan Zhang, and Yue Zhou, and Yue-Zhi Zhang, and Ke Shi
March 2024, Cell death & disease,
Chao Wu, and Xue-Qin Shang, and Zhi-Peng You, and Qi-Fang Jin, and Yu-Lan Zhang, and Yue Zhou, and Yue-Zhi Zhang, and Ke Shi
January 2022, Disease markers,
Chao Wu, and Xue-Qin Shang, and Zhi-Peng You, and Qi-Fang Jin, and Yu-Lan Zhang, and Yue Zhou, and Yue-Zhi Zhang, and Ke Shi
February 2015, Cancer research,
Chao Wu, and Xue-Qin Shang, and Zhi-Peng You, and Qi-Fang Jin, and Yu-Lan Zhang, and Yue Zhou, and Yue-Zhi Zhang, and Ke Shi
November 2022, Molecular neurobiology,
Chao Wu, and Xue-Qin Shang, and Zhi-Peng You, and Qi-Fang Jin, and Yu-Lan Zhang, and Yue Zhou, and Yue-Zhi Zhang, and Ke Shi
January 2024, Molecular biotechnology,
Chao Wu, and Xue-Qin Shang, and Zhi-Peng You, and Qi-Fang Jin, and Yu-Lan Zhang, and Yue Zhou, and Yue-Zhi Zhang, and Ke Shi
August 2022, Aging,
Chao Wu, and Xue-Qin Shang, and Zhi-Peng You, and Qi-Fang Jin, and Yu-Lan Zhang, and Yue Zhou, and Yue-Zhi Zhang, and Ke Shi
June 2020, European review for medical and pharmacological sciences,
Chao Wu, and Xue-Qin Shang, and Zhi-Peng You, and Qi-Fang Jin, and Yu-Lan Zhang, and Yue Zhou, and Yue-Zhi Zhang, and Ke Shi
July 2022, Genes & genomics,
Copied contents to your clipboard!